A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
Trial · NCT04091438
Participant flow20
How many started, completed or left each group, period by period.
1 to 20 of 20
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period 1 (1 Day) | STARTED | Sequence 1: TAK 925 112 mg + Placebo | 14 | |
| Treatment Period 1 (1 Day) | STARTED | Sequence 2: Placebo + TAK-925 112 mg | 14 | |
| Treatment Period 1 (1 Day) | Treated | Sequence 1: TAK 925 112 mg + Placebo | 13 | |
| Treatment Period 1 (1 Day) | Treated | Sequence 2: Placebo + TAK-925 112 mg | 14 | |
| Treatment Period 1 (1 Day) | COMPLETED | Sequence 1: TAK 925 112 mg + Placebo | 13 | |
| Treatment Period 1 (1 Day) | COMPLETED | Sequence 2: Placebo + TAK-925 112 mg | 14 | |
| Treatment Period 1 (1 Day) | NOT COMPLETED | Sequence 1: TAK 925 112 mg + Placebo | 1 | |
| Treatment Period 1 (1 Day) | NOT COMPLETED | Sequence 2: Placebo + TAK-925 112 mg | 0 | |
| Washout Period (1 Day) | STARTED | Sequence 1: TAK 925 112 mg + Placebo | 13 | |
| Washout Period (1 Day) | STARTED | Sequence 2: Placebo + TAK-925 112 mg | 14 | |
| Washout Period (1 Day) | COMPLETED | Sequence 1: TAK 925 112 mg + Placebo | 13 | |
| Washout Period (1 Day) | COMPLETED | Sequence 2: Placebo + TAK-925 112 mg | 12 | |
| Washout Period (1 Day) | NOT COMPLETED | Sequence 1: TAK 925 112 mg + Placebo | 0 | |
| Washout Period (1 Day) | NOT COMPLETED | Sequence 2: Placebo + TAK-925 112 mg | 2 | |
| Treatment Period 2 (1 Day) | STARTED | Sequence 1: TAK 925 112 mg + Placebo | 13 | |
| Treatment Period 2 (1 Day) | STARTED | Sequence 2: Placebo + TAK-925 112 mg | 12 | |
| Treatment Period 2 (1 Day) | COMPLETED | Sequence 1: TAK 925 112 mg + Placebo | 13 | |
| Treatment Period 2 (1 Day) | COMPLETED | Sequence 2: Placebo + TAK-925 112 mg | 12 | |
| Treatment Period 2 (1 Day) | NOT COMPLETED | Sequence 1: TAK 925 112 mg + Placebo | 0 | |
| Treatment Period 2 (1 Day) | NOT COMPLETED | Sequence 2: Placebo + TAK-925 112 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04091438/flow